Nabi kept by Bear Stearns at outperform

Nabi Biopharmaceuticals was maintained by Bear Stearns analyst Mark Schoenebaum at an outperform rating with a price target on the stock of $18 per share following a meeting with management. Bear Stearns expects phase III data on StaphVAX in late September or early October with further details in November followed with a filing by year-end, pointing to potential approval in late 2006. Nabi shares Tuesday were up $0.10, or 0.67%, at $14.98 on volume of 840,402 shares versus the three-month running average of 676,303 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.